COMP <GO>
TARS vs RLAY // DIVIDEND YIELD & FCF PAYOUT SAFETY
Tarsus Pharmaceuticals Inc. (NASDAQ) VS. Relay Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: TARS 7
— RLAY 1
■ METRIC PARITY
LAST: $74.20 (+2.98%) • MKT CAP: $3.66B
dividend-safety
0.00%
LAST: $19.47 (-1.12%) • MKT CAP: $4.27B
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TARS VS. RLAY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TARS | RLAY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -24.10% | -35.00% | +10.90 | TARS | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.61% | -5.53% | +4.92 | TARS | /fcf-yield <GO> |
| Operating Margin | -15.70% | -60.00% | +44.30 | TARS | /operating-margins <GO> |
| Net Profit Margin | -14.60% | -60.00% | +45.40 | TARS | /net-margins <GO> |
| Revenue Growth (YoY) | 146.70% | 53.40% | +93.30 | TARS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 10.19 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 4/9 | +1.00 | TARS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.1 | 50.0 | +5.12 | TARS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.66B | $4.27B | -$608.4M | RLAY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TARS REV | RLAY REV | TARS GROSS % | RLAY GROSS % | TARS FCF | RLAY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $451.4M | $15.4M | — | — | -$22.3M | -$235.9M |
| FY 2024 | $183.0M | $10.0M | — | — | -$84.6M | -$251.1M |
| FY 2023 | $17.4M | $25.5M | — | — | -$117.5M | -$300.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TARS // BETA —
RLAY // BETA —